Why is Accelerant Holdings stock surging today?

On today's trading session, Accelerant Holdings shares experienced a significant surge of 43.5%, trading at $19.52. This rally came shortly after the company announced a deal to be taken private by Thoma Bravo and announced impressive Q2 2026 earnings results. The all-cash transaction, valued at over $4 billion, offers $20.25 per share to both Class A and Class B stockholders, representing a 49% premium to the company's closing price on August 12, 2026.

The deal is expected to close in the first half of 2027, pending shareholder and regulatory approvals.

The company's earnings release added to the momentum, as Accelerant reported a Q2 adjusted EPS of $0.32, a 100% earnings surprise compared to the consensus estimate of $0.16. Revenue for the quarter also surpassed expectations, totaling $356.9 million, with a 30% increase over Wall Street forecasts. Net income for the quarter reached $80.0 million, up from just $13.1 million in the same period last year. Accelerant's Exchange Written Premium grew by 23% year-over-year to $1.32 billion.

Despite a downgrade from William Blair to Market Perform from Outperform following the buyout announcement, the broader market provided a supportive backdrop. The S&P 500 gained 0.6%, while the Nasdaq rose 0.8%. Entities affiliated with Altamont Capital Partners, who control about 82% of Accelerant’s voting rights, have already agreed to vote in favor of the merger, significantly reducing execution risk. The transaction is not financing-dependent, as Thoma Bravo has provided a full equity commitment to fund the purchase.

The combination of a premium-priced acquisition offer and a strong earnings report created an unusually powerful catalyst for Accelerant's stock movement. The stock's journey from a 52-week low of $9.18 to its current level of $19.52 highlights the recovery in underlying business fundamentals and the market's swift repricing towards the $20.25 deal price. The potential 6% annual fee provision offers shareholders additional protection if regulatory approvals cause delays.